Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,716.00
  • Today's Change1.50 / 0.09%
  • Shares traded888.60k
  • 1 Year change+21.92%
  • Beta0.5717
Data delayed at least 15 minutes, as of Feb 20 2026 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Santen Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, and sale of pharmaceuticals. The Company engages in global research and development, manufacture, sale, and marketing of pharmaceuticals in the ophthalmology field. The Company engages in prescription pharmaceuticals, over-the-counter pharmaceuticals, medical devices, and other businesses. The Company operates in Japan, Asia, Europe, the Middle East, and Africa (EMEA), China, and other regions.

  • Revenue in JPY (TTM)287.99bn
  • Net income in JPY30.60bn
  • Incorporated1925
  • Employees3.85k
  • Location
    Santen Pharmaceutical Co Ltd3-9-19, Shimo-Shinjo, Higashiyodogawa-kuOSAKA-SHI 530-8552JapanJPN
  • Phone+81 676648621
  • Fax+81 663593827
  • Websitehttps://www.santen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zeria Pharmaceutical Co Ltd86.61bn7.26bn113.79bn1.75k13.511.027.821.31164.79164.791,964.972,178.210.53661.273.2149,607,640.004.494.676.997.4772.7672.178.379.020.973911.410.298428.7515.307.6428.5227.7116.516.69
Mochida Pharmaceutical Co Ltd111.92bn6.42bn141.19bn1.51k21.421.0015.041.26181.16181.163,156.953,876.770.64271.673.0274,214,190.003.694.504.475.4448.4352.495.746.872.85--0.067843.012.210.651625.034.341.980.00
Kaken Pharmaceutical Co Ltd75.66bn-3.83bn189.36bn1.13k--1.11--2.50-97.11-97.111,980.563,850.390.40911.862.8067,195,380.00-2.075.99-2.426.8753.0956.17-5.0612.913.21--0.025759.5830.521.0573.77-6.3614.810.00
Kissei Pharmaceutical Co Ltd95.29bn14.14bn218.98bn1.78k13.940.901311.592.30337.47337.472,274.295,220.290.37481.852.8353,596,180.005.624.266.194.6048.2148.5914.9914.303.42--0.005832.4116.876.917.1833.5431.0413.97
Towa Pharmaceutical Co Ltd269.92bn21.44bn223.06bn4.79k9.941.125.120.8264435.61435.615,483.173,853.290.56951.493.3756,374,690.004.523.895.535.0736.7237.817.946.611.5432.770.551921.5213.8918.6517.395.5346.239.73
Sawai Group Holdings Co Ltd200.68bn-1.25bn275.26bn3.31k--1.5419.051.37-9.86-22.641,734.071,548.250.54451.283.4060,628,400.00-0.3389-0.2327-0.4542-0.318728.8932.95-0.6224-0.4751.08-1.040.4066191.656.880.7009-87.38-35.388.654.11
Tsumura & Co189.50bn29.01bn314.56bn4.27k10.591.007.381.66387.15387.152,524.844,095.990.3740.71062.4144,357,680.006.015.538.066.8547.6049.3916.0614.501.45--0.285631.6520.058.0094.1018.6923.0716.27
Nippon Shinyaku Co Ltd166.05bn29.85bn355.68bn2.24k11.421.209.822.14443.17443.172,465.264,211.800.54211.173.1974,028,980.009.7510.8910.8112.7467.2963.9317.9817.674.04--0.008930.588.086.5625.9414.0680.487.59
Hisamitsu Pharmaceutical Co Inc159.27bn19.99bn469.40bn2.80k22.551.6317.052.95276.99276.992,208.133,837.320.47042.643.4256,901,390.006.044.347.254.9959.0557.8312.8410.323.28--0.008650.2910.092.0455.763.0829.890.7127
Santen Pharmaceutical Co Ltd287.99bn30.60bn552.54bn3.85k18.631.9511.341.9292.0392.03865.27880.970.72052.264.1874,823,070.007.633.949.434.9356.8958.9710.596.011.89--0.175771.86-0.64944.4336.098.943.615.92
Rohto Pharmaceutical Co Ltd335.80bn34.48bn571.32bn9.14k16.311.9010.981.70148.28148.281,444.671,272.140.77682.324.5536,723,640.008.028.5911.2011.7056.0657.7810.3310.571.43--0.145221.1213.9510.380.226315.0110.4222.59
Sumitomo Pharma Co Ltd453.40bn110.09bn1.17tn3.83k10.584.038.862.57277.11277.111,141.22727.280.54381.953.99118,318,100.0013.20-5.4923.02-8.4959.2467.8824.28-13.241.014.170.4726--26.79-3.75107.50-10.32-0.4856--
Ono Pharmaceutical Co Ltd509.35bn62.40bn1.29tn4.29k19.541.4513.022.54132.76132.761,084.011,786.880.47022.143.38118,811,500.005.7710.786.6112.3769.7973.2312.2721.232.56125.260.128336.33-3.1410.73-60.89-3.47-18.6612.20
Data as of Feb 20 2026. Currency figures normalised to Santen Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

37.37%Per cent of shares held by top holders
HolderShares% Held
Silchester International Investors LLPas of 07 Oct 202531.56m9.79%
Nomura Asset Management Co., Ltd.as of 31 May 202419.14m5.94%
Black Creek Investment Management, Inc.as of 15 Oct 202413.74m4.26%
The Vanguard Group, Inc.as of 04 Feb 202611.40m3.54%
Norges Bank Investment Managementas of 30 Jun 20259.69m3.01%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Sep 20259.66m3.00%
Amova Asset Management Co., Ltd.as of 15 Sep 20259.29m2.88%
BlackRock Japan Co. Ltd.as of 29 Nov 20247.04m2.18%
Daiwa Asset Management Co. Ltd.as of 30 Jan 20264.68m1.45%
BlackRock Fund Advisorsas of 29 Nov 20244.21m1.31%
More ▼
Data from 31 Dec 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.